In the past week, DNA stock has gone down by -7.21%, with a monthly gain of 18.40% and a quarterly plunge of -1.03%. The volatility ratio for the week is 5.03%, and the volatility levels for the last 30 days are 7.16% for Ginkgo Bioworks Holdings Inc. The simple moving average for the last 20 days is -1.91% for DNA stock, with a simple moving average of 14.04% for the last 200 days.
Is It Worth Investing in Ginkgo Bioworks Holdings Inc. (NYSE: DNA) Right Now?
Additionally, the 36-month beta value for DNA is 1.18. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 1 rating it as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The average price predicted by analysts for DNA is $4.02, which is $2.09 above the current price. The public float for DNA is 1.43B and currently, short sellers hold a 14.46% ratio of that float. The average trading volume of DNA on September 18, 2023 was 22.26M shares.
DNA) stock’s latest price update
The stock of Ginkgo Bioworks Holdings Inc. (NYSE: DNA) has decreased by -1.53 when compared to last closing price of 1.96. Despite this, the company has experienced a -7.21% fall in its stock price over the last five trading sessions. InvestorPlace reported 2023-09-15 that Pursuing undervalued Cathie Wood stocks radiates a magnetic allure for investors aiming for a hefty financial breakthrough. The stocks favored by Wood are risky but grounded in foresight, offering tremendous long-term upside potential.
Analysts’ Opinion of DNA
Many brokerage firms have already submitted their reports for DNA stocks, with Goldman repeating the rating for DNA by listing it as a “Sell.” The predicted price for DNA in the upcoming period, according to Goldman is $1.25 based on the research report published on June 02, 2023 of the current year 2023.
DNA Trading at -5.92% from the 50-Day Moving Average
After a stumble in the market that brought DNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.17% of loss for the given period.
Volatility was left at 7.16%, however, over the last 30 days, the volatility rate increased by 5.03%, as shares surge +19.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.21% upper at present.
During the last 5 trading sessions, DNA fell by -7.21%, which changed the moving average for the period of 200-days by +4.89% in comparison to the 20-day moving average, which settled at $1.9835. In addition, Ginkgo Bioworks Holdings Inc. saw 14.20% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNA starting from Kelly Jason R, who sale 100,000 shares at the price of $2.00 back on Sep 14. After this action, Kelly Jason R now owns 6,894,680 shares of Ginkgo Bioworks Holdings Inc., valued at $199,500 using the latest closing price.
Canton Barry, the 10% Owner of Ginkgo Bioworks Holdings Inc., sale 37,650 shares at $2.00 during a trade that took place back on Sep 14, which means that Canton Barry is holding 12,901,644 shares at $75,149 based on the most recent closing price.
Stock Fundamentals for DNA
Current profitability levels for the company are sitting at:
- -452.56 for the present operating margin
- +44.35 for the gross margin
The net margin for Ginkgo Bioworks Holdings Inc. stands at -440.63. The total capital return value is set at -114.71, while invested capital returns managed to touch -114.49. Equity return is now at value -77.90, with -53.70 for asset returns.
Based on Ginkgo Bioworks Holdings Inc. (DNA), the company’s capital structure generated 25.49 points at debt to equity in total, while total debt to capital is 20.31. Total debt to assets is 17.43, with long-term debt to equity ratio resting at 23.80. Finally, the long-term debt to capital ratio is 18.97.
When we switch over and look at the enterprise to sales, we see a ratio of 9.01, with the company’s debt to enterprise value settled at 0.23. The receivables turnover for the company is 4.08 and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.38.
Conclusion
In conclusion, Ginkgo Bioworks Holdings Inc. (DNA) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
